Early study tests immune cells given into the brain fluid for children with brain tumors
Original title: Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is an early trial in people that mainly checked safety and dose, not whether it works.
The short version
A new immune cell treatment, given into the fluid spaces of the brain, was tolerated by young people with hard to treat brain tumors.
What was studied. This was a phase 1 trial in children and young adults with brain and spinal cord tumors that came back or did not respond to treatment. Doctors made immune cells, called CAR T cells, that target a marker named B7-H3, then gave them as repeated infusions into the fluid spaces of the brain.
What they found. Of 36 patients who joined, the cells were made successfully for 35, and 26 received the treatment. The typical age was 10 years, with a range of 1 to 26. Patients got 181 doses in all, and the most common problems were headache in 26 people, fever in 15, and nausea in 14. No side effect was bad enough to stop the dose from being raised. The typical time patients lived after their first dose was 11.5 months, ranging from 3.2 months to 21.4 months depending on the tumor type, and two patients had their tumor shrink part way.
What this means, and what it doesn't
What it could mean: It looks possible to give these immune cells into the brain fluid again and again without severe side effects. That is what an early trial is meant to show. It gives researchers a reason to keep testing this approach in larger studies.
What it doesn't mean: This does not mean a new treatment is ready. It was a phase 1 trial, the first and earliest stage of testing in people, and it was mainly checking safety and dose. Only two patients had a tumor that shrank part way, and the study was not built to prove the treatment works. It is not approved, it is not part of normal care, and it is not a cure.
Source: PubMed, July 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.